| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $821,779 ) |
| | 2025 | 2025 | TALUS BIOSCIENCE INC | 550 17TH AVE | SEATTLE | WA | 98122-5795 | KING | USA | R44TR004349 | Activity-based regulome profiling for the discovery of covalent transcription factor inhibitors | 000 | 3 | NIH | 1/16/2025 | $821,779 |
| | 2025 | 2024 | TALUS BIOSCIENCE INC | 550 17TH AVE | SEATTLE | WA | 98122-5795 | KING | USA | R44TR004349 | Activity-based regulome profiling for the discovery of covalent transcription factor inhibitors | 002 | 2 | NIH | 2/21/2025 | $0 |
| | 2025 | 2023 | TALUS BIOSCIENCE INC | 550 17TH AVE | SEATTLE | WA | 98122-5795 | KING | USA | R44TR004349 | Activity-based regulome profiling for the discovery of covalent transcription factor inhibitors | 001 | 1 | NIH | 2/21/2025 | $0 |
|
| Issue Date FY: 2024 ( Subtotal = $1,821,764 ) |
| | 2024 | 2024 | TALUS BIOSCIENCE INC | 550 17TH AVE | SEATTLE | WA | 98122-5795 | KING | USA | R44CA268146 | Simultaneous pharmacological profiling of oncogenic gene fusion proteins in cancer | 000 | 3 | NIH | 6/12/2024 | $1,000,000 |
| | 2024 | 2024 | TALUS BIOSCIENCE INC | 550 17TH AVE | SEATTLE | WA | 98122-5795 | KING | USA | R44TR004349 | Activity-based regulome profiling for the discovery of covalent transcription factor inhibitors | 000 | 2 | NIH | 2/28/2024 | $821,779 |
| | 2024 | 2022 | TALUS BIOSCIENCE INC | 550 17TH AVE | SEATTLE | WA | 98122-5795 | KING | USA | R42CA268146 | Simultaneous pharmacological profiling of oncogenic gene fusion proteins in cancer | 000 | 1 | NIH | 12/22/2023 | $0 |
| | 2024 | 2022 | TALUS BIOSCIENCE INC | 550 17TH AVE | SEATTLE | WA | 98122-5795 | KING | USA | R43TR004221 | Illuminating the "dark" kinases - effects on proteome translocation and chromatin binding | 000 | 1 | NIH | 2/20/2024 | -$15 |
|
| Issue Date FY: 2023 ( Subtotal = $1,705,906 ) |
| | 2023 | 2023 | TALUS BIOSCIENCE, INC. | 2300 VASHON CT NE | RENTON | WA | 98059-3610 | KING | USA | R44CA268146 | Simultaneous pharmacological profiling of oncogenic gene fusion proteins in cancer | 000 | 2 | NIH | 6/16/2023 | $1,000,000 |
| | 2023 | 2023 | TALUS BIOSCIENCE INC | 550 17TH AVE | SEATTLE | WA | 98122-5795 | KING | USA | R43GM146472 | Deep learning methods to accelerate discoveryof drugs targeting gene regulatory proteins | 000 | 1 | NIH | 9/20/2023 | $398,441 |
| | 2023 | 2023 | TALUS BIOSCIENCE INC | 550 17TH AVE | SEATTLE | WA | 98122-5795 | KING | USA | R44TR004349 | Activity-based regulome profiling for the discovery of covalent transcription factor inhibitors | 001 | 1 | NIH | 8/21/2023 | $0 |
| | 2023 | 2023 | TALUS BIOSCIENCE INC | 550 17TH AVE | SEATTLE | WA | 98122-5795 | KING | USA | R44TR004349 | Activity-based regulome profiling for the discovery of covalent transcription factor inhibitors | 000 | 1 | NIH | 8/14/2023 | $307,465 |
|
| Issue Date FY: 2022 ( Subtotal = $788,867 ) |
| | 2022 | 2022 | TALUS BIOSCIENCE, INC. | 2300 VASHON CT NE | RENTON | WA | 98059-3610 | KING | USA | R42CA268146 | Simultaneous pharmacological profiling of oncogenic gene fusion proteins in cancer | 000 | 1 | NIH | 3/24/2022 | $400,000 |
| | 2022 | 2022 | TALUS BIOSCIENCE, INC. | 2300 VASHON CT NE | RENTON | WA | 98059-3610 | KING | USA | R42CA268146 | Simultaneous pharmacological profiling of oncogenic gene fusion proteins in cancer | 001 | 1 | NIH | 8/5/2022 | $55,000 |
| | 2022 | 2022 | TALUS BIOSCIENCE, INC. | 2300 VASHON CT NE | RENTON | WA | 98059-3610 | KING | USA | R43TR004221 | Illuminating the "dark" kinases - effects on proteome translocation and chromatin binding | 000 | 1 | NIH | 3/15/2022 | $333,867 |
|
|
